NASDAQ: ACADAcadia Pharmaceuticals Inc Stock
$20.68-1.50 (-6.76%)
Updated Sep 25, 2026
ACADIA Pharmaceuticals shares are trading... find out Why ACAD Price Moved with a free WallStreetZen account
Why Price MovedACAD Price
$20.68
Fair Value Price
-$9.85
Market Cap
$3.56B
52 Week Low
$19.69
52 Week High
$30.96
P/E
9.19x
P/B
2.73x
P/S
3.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.14B
Earnings
$380.48M
Gross Margin
91.1%
Operating Margin
10.66%
Profit Margin
33.4%
Debt to Equity
0.33
Operating Cash Flow
$160M
Beta
0.98
Next Earnings
Nov 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ACAD Overview
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACAD's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +17.17% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ACAD
Ranked#32 of 464
Ranked#32 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.77 | A | |
| $7.75 | A | |
| $360.85 | A |
Be the first to know about important ACAD news, forecast changes, insider trades & much more!
ACAD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACAD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACAD ($20.68) is overvalued by 309.88% relative to our estimate of its Fair Value price of -$9.85 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ACAD ($20.68) is not significantly undervalued (309.88%) relative to our estimate of its Fair Value price of -$9.85 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACAD is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACAD due diligence checks available for Premium users.
Valuation
ACAD fair value
Fair Value of ACAD stock based on Discounted Cash Flow (DCF)
Price
$20.68
Fair Value
-$9.85
Undervalued by
309.88%
ACAD ($20.68) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACAD ($20.68) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACAD is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACAD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
9.19x
Industry
14.87x
Market
47.39x
ACAD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ACAD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ACAD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.73x
Industry
5.19x
ACAD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACAD's financial health
Profit margin
Revenue
$308.0M
Net Income
$31.5M
Profit Margin
10.2%
ACAD's Earnings (EBIT) of $121.37M... subscribe to Premium to read more.
Interest Coverage Financials
ACAD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7B
Liabilities
$436.3M
Debt to equity
0.33
ACAD's short-term assets ($1.22B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACAD's short-term assets ($1.22B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACAD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACAD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$100.8M
Investing
-$8.5M
Financing
$10.5M
ACAD's operating cash flow ($160.32M)... subscribe to Premium to read more.
Debt Coverage Financials
ACAD vs Biotech Stocks
Acadia Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.